JAMIE SIMONIS: Open Payments
NPI 1831836055 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$330 in 16 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $425 · 2025 $330
Food & beverage: $330
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $54 |
| Novo Nordisk Inc | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Lilly USA, LLC | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Edwards Lifesciences Corporation | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Braeburn Inc. | 1 | $19 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, Ozempic, GEMTESA, SAPIEN 3 Ultra RESILIA, Veozah, Leqembi, MOUNJARO.
Industry payments across AZ — which companies pay providers there.
